Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, People's Republic of China.
Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, People's Republic of China.
Ann Allergy Asthma Immunol. 2021 May;126(5):524-534. doi: 10.1016/j.anai.2021.02.013. Epub 2021 Feb 18.
It is unclear whether asthma has an influence on contracting coronavirus disease 2019 (COVID-19) or having worse outcomes from COVID-19 disease.
To explore the prevalence of asthma in patients with COVID-19 and the relationship between asthma and patients with COVID-19 with poor outcomes.
The pooled prevalence of asthma in patients with COVID-19 and corresponding 95% confidence interval (CI) were estimated. The pooled effect size (ES) was used to evaluate the association between asthma and patients with COVID-19 with poor outcomes.
The pooled prevalence of asthma in patients with COVID-19 worldwide was 8.3% (95% CI, 7.6-9.0) based on 116 articles (119 studies) with 403,392 cases. The pooled ES based on unadjusted effect estimates revealed that asthma was not associated with reduced risk of poor outcomes in patients with COVID-19 (ES, 0.91; 95% CI, 0.78-1.06). Similarly, the pooled ES based on unadjusted effect estimates revealed that asthma was not associated with the reduced risk of mortality in patients with COVID-19 (ES, 0.88; 95% CI, 0.73-1.05). However, the pooled ES based on adjusted effect estimates indicated that asthma was significantly associated with reduced risk of mortality in patients with COVID-19 (ES 0.80, 95% CI 0.74-0.86).
The pooled prevalence of asthma in patients with COVID-19 was similar to that in the general population, and asthma might be an independent protective factor for the death of patients with COVID-19, which suggests that we should pay high attention to patients co-infected asthma and COVID-19 and take locally tailored interventions and treatment. Further well-designed studies with large sample sizes are required to verify our findings.
目前尚不清楚哮喘是否会影响感染 2019 年冠状病毒病（COVID-19）或导致 COVID-19 疾病的不良结局。
探讨 COVID-19 患者中哮喘的患病率，以及哮喘与 COVID-19 不良结局患者之间的关系。
估计 COVID-19 患者中哮喘的汇总患病率和相应的 95%置信区间（CI）。采用汇总效应量（ES）评估哮喘与 COVID-19 不良结局患者之间的关系。
基于 116 篇文章（119 项研究）和 403392 例患者，全球 COVID-19 患者中哮喘的汇总患病率为 8.3%（95%CI，7.6%-9.0%）。基于未调整效应估计值的汇总 ES 显示，哮喘与 COVID-19 患者不良结局风险降低无关（ES，0.91；95%CI，0.78-1.06）。同样，基于未调整效应估计值的汇总 ES 显示，哮喘与 COVID-19 患者的死亡率降低无关（ES，0.88；95%CI，0.73-1.05）。然而，基于调整效应估计值的汇总 ES 表明，哮喘与 COVID-19 患者的死亡率降低显著相关（ES 0.80，95%CI 0.74-0.86）。
COVID-19 患者中哮喘的患病率与普通人群相似，哮喘可能是 COVID-19 患者死亡的独立保护因素，这表明我们应高度关注合并哮喘和 COVID-19 的患者，并采取因地制宜的干预和治疗措施。需要进一步开展设计良好、样本量大的研究来验证我们的研究结果。
